Clinical Trial Update: CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CT7, MAGE-A3, and WT1 mRNA-electroporated autologous Langerhans-type dendritic cells as consolidation after autologous stem cell transp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CT7, MAGE-A3, and WT1 mRNA-electroporated autologous Langerhans-type dendritic cells

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2024-02-09